We’re Making Headlines by Transforming Innovation Read All About How We are Making an Impact Here! AlphaMeld Corporation and VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance to Transform Metabolic and Liver Disease Therapeutics Read More » AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform Read More » InveniAI Announces Launch of AlphaMeld® Corporation and Major Milestone Updates to Reflect Cutting-Edge Innovation in AI-Driven Drug Discovery Read More » InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery Read More » InveniAI’s AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development Read More » InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration Read More » InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools Read More » InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas Read More » InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates Read More » Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration Read More » InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis Read More » InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration Read More » InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration Read More » InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways Read More » InveniAI Enters Strategic Artificial Intelligence (AI) and Machine Learning (ML) Focused Collaboration with GlaxoSmithKline Consumer Healthcare Read More » InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis Read More » InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis Read More » InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite Read More » InveniAI Launches Suite of Products Powered by AlphaMeld® an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences Read More » InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU Read More » Microsoft Features InveniAI in their Series, Now This Future: “AI for Change” Read More » InveniAI Featured in The Guardian’s Rare Disease Campaign Read More » InveniAI Enters Strategic Artificial Intelligence Collaboration with Kyowa Hakko Kirin Read More »
AlphaMeld Corporation and VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance to Transform Metabolic and Liver Disease Therapeutics Read More »
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform Read More »
InveniAI Announces Launch of AlphaMeld® Corporation and Major Milestone Updates to Reflect Cutting-Edge Innovation in AI-Driven Drug Discovery Read More »
InveniAI’s AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development Read More »
InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools Read More »
InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas Read More »
InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates Read More »
Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration Read More »
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis Read More »
InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways Read More »
InveniAI Enters Strategic Artificial Intelligence (AI) and Machine Learning (ML) Focused Collaboration with GlaxoSmithKline Consumer Healthcare Read More »
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis Read More »
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis Read More »
InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite Read More »
InveniAI Launches Suite of Products Powered by AlphaMeld® an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences Read More »
InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU Read More »
